Yeah but it was a way after ILFS crisis (around 2018) and this guidance was given in Sep2020 (after covid) besides my point was not regarding any specific details but was to highlight that we need to take whatever they mentioned in IP with a lot of salt. Thanks!
Disc. Has holding. may be biased.
Posts in category Value Pickr
Indiabulls Housing – A compounder from here? (10-06-2024)
Royal Orchid Hotels – Available at good valuation! (10-06-2024)
Multiple factors -
The Hotel Industry is the strongest at the top end - 4 star, 5 star level. Royal Orchid has a large presence at the 3-star level. That’s one source of skepticism
FY 25 is gonna be a year of consolidation. That’s another
Royal Orchid / Regenta - is still not an established brand. I think, they need to put in another 2-3 yrs of good work in areas of quality control etc to make their brand - more robust
Krishna Defence & Allied Industries Ltd – SME play on Shipbuilding (10-06-2024)
Detailed risk analysis is missing. Please comply. Till then the thread remains locked.
Bajaj Finance Limited (10-06-2024)
How is IPO of a subsidiary good for Bajaj finance?
Demerger will give the existing shareholder the shares of demerged entity. IPO will only make the parent a holding company and hence will result in holding company discount.
Disc: Invested in Bajaj finance, so opinions are biased.
Borosil Limited (10-06-2024)
yes it will be priced as zero acquisition value
Force Motors – racing ahead! (10-06-2024)
Total sales down from May 2023 (2609) to 2523 in May 2024
Wockhardt: an NiCE story (10-06-2024)
Wockhardt AR is out and there some details on the other molecules currently under trials in various stages. Some updates on WCK 4282 and WCK 6777 are new
WCK 5222 (Cefepime+Zidebactam) - USFDA Phase 3 with 392 patients signed up and expected to complete in Q4 FY25. Indian Meropenem resistance trial permission from CDSCO says the number of patients is upto 60 and as per company update it is expected to be complete by Nov '24. Compassionate use so far for 30 patients with 100% recovery rate
WCK 4282 (Cefepime + Tazobactam) - Looks like there’s a combined ph2 and ph3 trial going to get underway in India this month. Permission from CDSCO has additional details. The total subjects could be upto 324. What’s also interesting is that it says potential support from “National Biopharma Mission” - not sure if this indicates financial support for the trial.
National Biopharma Mission in its charter says its funded by GoI and World Bank for development of drugs
WCK 4873 (Nafithromycin) - It looks like India phase 3 is successfully completed and the company has filed NDA with DCGI and it should get approved by Q3 FY25 and be in the market by Q4 FY25
WCK 6777 - (Ertapenem + Zidebactam) - Phase 1 was completed as per US clinical trials. It is highly likely that this will also undergo a combined phase 2+phase 3 trial like WCK 5222.
On the two products which are already launched in India
WCK 771 & WCK 2349 (Emrok and Emrok (0)) - Anti-MRSA drug. 65000 patients have been successfully treated in India and registrations have been filed in 10 countries (Kenya, Uganda, Tanzania, Saudi, Russia mentioned in different parts of AR) and approval is expected in FY25. In India the AR says the use is expanding from CABP to bone and joint infections and febrile neutropenia patients.
Compiling the information into this thread for tracking purpose
Disc: Invested
Imagicaa – Another Player in Theme Park Business (10-06-2024)
You need to put up detailed risk analysis/negatives/threats/competition etc. Till you comply, the thread remains.locked.
MPS Ltd (10-06-2024)
Q4 Concall;
Question : What white spaces do you still see now on those three verticals we operate and where we’re trying to get more acquisitions? We have a full book of products. Now the only thing is that we have to scale up. And you are contradicting that. You are saying that we still can go for more acquisitions or whether they will be bolt-on acquisitions or whether they will be in the same area just to ramp up the scale?
Answer by Rahul Arora: More than most, yes. I would not say from a capability standpoint we possess everything… There are still opportunities for capability expansion that allow us to move up/down the value chain. So we’re looking at those types of opportunities.We’re looking at opportunities that expand our geographic reach as well. For example, in FY’24, we expanded into Australia, New Zealand, as well as in China. There are still regions like, the Middle East as well as Latin America that we’re not currently very strong in. Also, certain parts of Europe where we’re not very strong. So there’s a geographic play that we’re looking at as well.
We are also looking to actively accelerate the education space. Today in the education space, a bulk of our revenue comes from K-12 as well as through publishing and our goal is to scale that into higher ed and specifically within higher ed within adult learning and educational institutes. So there’s still much juice left for us to acquire in terms of capability expansion, geographic expansion, as well as adjacent market expansion. So we’re looking at all three sectors.
Dhinakaran Portfolio (10-06-2024)
Quick update on the Portfolio. No changes since few years. I am trying to deploy more capital, Market remains out of my comfort zone and testing my patience I am holding up still. I have also started my position in the US markets. Comments most welcome.
Instrument | % Allocation |
---|---|
TVSMOTOR | 9 |
BAJAJFINSV | 8 |
HDFCAMC | 6 |
CDSL | 5 |
DMART | 5 |
TCS | 5 |
BRITANNIA | 4 |
ICICIBANK | 4 |
TATAELXSI | 4 |
TITAN | 4 |
ASIANPAINT | 3 |
ASTRAL | 3 |
CCL | 3 |
CHOLAFIN | 3 |
MAYURUNIQ | 3 |
PAKKA | 3 |
PAUSHAKLTD | 3 |
RELAXO | 3 |
AJANTPHARM | 2 |
AVANTIFEED | 2 |
CROMPTON | 2 |
FINPIPE | 2 |
HATSUN | 2 |
HDFCBANK | 2 |
HDFCLIFE | 2 |
JUBLFOOD | 2 |
LAOPALA | 2 |
US Investments: